vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and WEBSTER FINANCIAL CORP (WBS). Click either name above to swap in a different company.
WEBSTER FINANCIAL CORP is the larger business by last-quarter revenue ($735.9M vs $722.5M, roughly 1.0× Amneal Pharmaceuticals, Inc.). WEBSTER FINANCIAL CORP runs the higher net margin — 33.5% vs 10.8%, a 22.7% gap on every dollar of revenue. Over the past eight quarters, WEBSTER FINANCIAL CORP's revenue compounded faster (9.4% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Webster Bank is an American commercial bank based in Stamford, Connecticut. It has 177 branches and 316 ATMs located in Connecticut; Massachusetts; Rhode Island; New Jersey; Westchester, Orange, Ulster, and Rockland counties in New York as well as New York City.
AMRX vs WBS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $735.9M |
| Net Profit | $78.0M | $246.2M |
| Gross Margin | 44.3% | — |
| Operating Margin | 19.6% | — |
| Net Margin | 10.8% | 33.5% |
| Revenue YoY | 3.9% | — |
| Net Profit YoY | 410.5% | 8.5% |
| EPS (diluted) | $0.19 | $1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $735.9M | ||
| Q4 25 | $814.3M | $746.2M | ||
| Q3 25 | $784.5M | $732.6M | ||
| Q2 25 | $724.5M | $715.8M | ||
| Q1 25 | $695.4M | $704.8M | ||
| Q4 24 | $730.5M | $661.0M | ||
| Q3 24 | $702.5M | $647.6M | ||
| Q2 24 | $701.8M | $614.6M |
| Q1 26 | $78.0M | $246.2M | ||
| Q4 25 | $35.1M | $255.8M | ||
| Q3 25 | $2.4M | $261.2M | ||
| Q2 25 | $22.4M | $258.8M | ||
| Q1 25 | $12.2M | $226.9M | ||
| Q4 24 | $-31.1M | $177.8M | ||
| Q3 24 | $-156.0K | $193.0M | ||
| Q2 24 | $6.0M | $181.6M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 13.8% | 48.6% | ||
| Q3 25 | 9.0% | 51.3% | ||
| Q2 25 | 15.4% | 51.7% | ||
| Q1 25 | 14.4% | 51.2% | ||
| Q4 24 | 10.4% | 48.5% | ||
| Q3 24 | 12.6% | 46.1% | ||
| Q2 24 | 13.6% | 47.0% |
| Q1 26 | 10.8% | 33.5% | ||
| Q4 25 | 4.3% | 34.3% | ||
| Q3 25 | 0.3% | 35.7% | ||
| Q2 25 | 3.1% | 36.2% | ||
| Q1 25 | 1.8% | 32.2% | ||
| Q4 24 | -4.3% | 26.9% | ||
| Q3 24 | -0.0% | 29.8% | ||
| Q2 24 | 0.9% | 29.6% |
| Q1 26 | $0.19 | $1.50 | ||
| Q4 25 | $0.10 | $1.54 | ||
| Q3 25 | $0.01 | $1.54 | ||
| Q2 25 | $0.07 | $1.52 | ||
| Q1 25 | $0.04 | $1.30 | ||
| Q4 24 | $-0.10 | $1.01 | ||
| Q3 24 | $0.00 | $1.10 | ||
| Q2 24 | $0.02 | $1.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $197.7M | — |
| Total DebtLower is stronger | — | $738.3M |
| Stockholders' EquityBook value | — | $9.6B |
| Total Assets | $3.5B | $85.6B |
| Debt / EquityLower = less leverage | — | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $197.7M | — | ||
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — |
| Q1 26 | — | $738.3M | ||
| Q4 25 | $2.6B | $739.5M | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.2B | $905.6M | ||
| Q1 25 | $2.2B | $907.4M | ||
| Q4 24 | $2.4B | $909.2M | ||
| Q3 24 | $2.4B | $911.0M | ||
| Q2 24 | $2.4B | $912.7M |
| Q1 26 | — | $9.6B | ||
| Q4 25 | $-70.8M | $9.5B | ||
| Q3 25 | $-109.5M | $9.5B | ||
| Q2 25 | $-112.1M | $9.3B | ||
| Q1 25 | $-131.7M | $9.2B | ||
| Q4 24 | $-109.3M | $9.1B | ||
| Q3 24 | $-93.4M | $9.2B | ||
| Q2 24 | $-57.5M | $8.8B |
| Q1 26 | $3.5B | $85.6B | ||
| Q4 25 | $3.7B | $84.1B | ||
| Q3 25 | $3.6B | $83.2B | ||
| Q2 25 | $3.4B | $81.9B | ||
| Q1 25 | $3.4B | $80.3B | ||
| Q4 24 | $3.5B | $79.0B | ||
| Q3 24 | $3.5B | $79.5B | ||
| Q2 24 | $3.5B | $76.8B |
| Q1 26 | — | 0.08× | ||
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.13× | ||
| Q2 25 | — | 0.10× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
Segment breakdown not available.
WBS
| Net Interest Income | $634.4M | 86% |
| Noninterest Income | $101.5M | 14% |
